Search results
Showing 496 to 510 of 985 results for drug therapy
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)
Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.
This quality standard covers identifying and supporting adults and young people (aged 10 and over) who may have an alcohol-use disorder and caring for people with alcohol-related health problems, as well as support for their families and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS11Show all sections
Sections for QS11
- Quality statements
- Quality statement 1: Use of validated alcohol questionnaires
- Quality statement 2: Community support networks and self-help groups
- Quality statement 3: Triage assessment in specialist alcohol services
- Quality statement 4: Acute alcohol withdrawal
- Quality statement 5: Interventions to prevent relapse after unplanned withdrawal from alcohol in hospital
- Update information
- About this quality standard
Evidence-based recommendations on bimekizumab (Bimzelx) for treating axial spondyloarthritis in adults.
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults.
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)
Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .